Onco Wiki / Indication

Carcinome à cellules squameuses du pénis · ligne 1 · Pembrolizumab en monothérapie (MSI-H mCRC 1L)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.

Source YAML: dossier complet

Ligne thérapeutique1
Voieagressif
Régime liéREG-PEMBROLIZUMAB-MSI-MONO
IDIND-PENILE-SCC-METASTATIC-1L-MSI-H-PEMBRO
TypeIndication
Étatreviewed 2026-07-11 | pending_clinical_signoff
MaladiesDIS-PENILE-SCC
SourcesSRC-EAU-PENILE-2024

Notes

STUB — bonus/4th indication beyond the 3 explicitly requested in this authoring pass, added because the DIS-PENILE-SCC narrative explicitly names "pembrolizumab in MSI-H subset" and nearly every referenced entity already exists in the KB (DRUG-PEMBROLIZUMAB, REG-PEMBROLIZUMAB-MSI-MONO, BIO-MSI-STATUS, CI-PEMBROLIZUMAB-AUTOIMMUNE, RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK) — low-invention-risk, high narrative fidelity. New RF-PENILE-SCC-MSI-H-ACTIONABILITY authored to gate this branch in ALGO-PENILE-SCC-1L. Independent review removed a proposed secondary citation to SRC-NCCN-BLADDER-2025 (that source is the NCCN Bladder Cancer guideline, relates_to_diseases: [DIS-UROTHELIAL] only — it does not cover penile cancer and should not be cited here; SRC-EAU-PENILE-2024 alone supports this indication). Requires medical-oncology co-lead signoff before clinical publication (CHARTER §6.1; dev-mode-exempted for draft merge).

Utilisé par

Algorithmes

Indication